Predictive Factors of Hyperlipidemia in HIV-Infected Subjects Receiving Lopinavir/Ritonavir
Marco Bongiovanni(Luigi Sacco Hospital), Antonella d’Arminio Monforte(University of Milan), Patrizia Biasi(University of Milan), Fulvio Adorni(Institute of Biomedical Technologies), Paola Cicconi(University of Oxford), Simona Landonio(ASST Fatebenefratelli Sacco), Federica Tordato(Humanitas University), Teresa Bini(Ospedale San Paolo), Elisabetta Chiesa(University of Milan), Paola Meraviglia(Luigi Sacco Hospital), Letizia Testa(Ospedale di Circolo di Busto Arsizio), Antonio Di Biagio
Cited by 17
Related Papers
Female gender is associated with long COVID syndrome: a prospective cohort study
|Clinical Microbiology and Infection|2021|656
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Discontinuation of Secondary Prophylaxis against<i>Pneumocystis carinii</i>Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy
|New England Journal of Medicine|2001|168
Cardiovascular risk and dyslipidemia among persons living with HIV: a review
|BMC Infectious Diseases|2017|152